What is the fair value of MannKind Corp (NASDAQ-MNKD) stock?

The current fair value estimate for MannKind Corp (NASDAQ-MNKD) is $3.97. This implies an estimated upside of 12.1% versus the current market price.

Is MannKind Corp (NASDAQ-MNKD) undervalued or overvalued?

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 12.1% versus the current market price.

What is the analyst price target for NASDAQ-MNKD stock?

The available analyst price target for MannKind Corp (NASDAQ-MNKD) is $7.97. The analyst target implies estimated upside of 125.1%.

How is the financial health of MannKind Corp?

The current financial health read for MannKind Corp (NASDAQ-MNKD) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is MannKind Corp's next earnings date?

The next earnings date currently listed for MannKind Corp (NASDAQ-MNKD) is November 10, 2026.

Does MannKind Corp (NASDAQ-MNKD) pay dividends?

The latest available data indicates no current dividend yield for MannKind Corp (NASDAQ-MNKD).

What is the market capitalization of MannKind Corp?

The current market capitalization listed for MannKind Corp is 1.141 B.

What is the enterprise value of MannKind Corp?

The current enterprise value listed for MannKind Corp is 1.471 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for MannKind Corp?

The ticker symbol for MannKind Corp is NASDAQ-MNKD, and the stock is listed on NASDAQ.

Where is MannKind Corp (NASDAQ-MNKD) listed?

MannKind Corp (NASDAQ-MNKD) is listed on NASDAQ.

What is the debt-to-total-capital ratio for MannKind Corp?

The current debt-to-total-capital ratio listed for MannKind Corp is 27.4%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for MannKind Corp?

The free float listed for MannKind Corp is 92.5%. Free float helps investors understand how much of the share base is available for public trading.

MannKind Corp (MNKD) Fair Value & Stock Analysis

MannKind Corp (MNKD)

MannKind Corp. is a biotechnology company focused on therapies for chronic and serious diseases. Its commercial portfolio includes Afrezza, an inhaled insulin for adults with diabetes; Furoscix, a furosemide injection used to treat edema in certain pediatric patients with chronic heart failure or chronic kidney disease; V-Go, a wearable insulin delivery device; and Tyvaso DPI for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company is also developing product candidates for orphan lung diseases, including MNKD-201 for idiopathic pulmonary fibrosis and MNKD-701. MannKind has collaboration and license arrangements with United Therapeutics for Tyvaso DPI and with Thirona related to pulmonary fibrosis research. Founded in 1991, the company is headquartered in Danbury, Connecticut.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Dividend Yield	Next Earnings Date	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Free Cash Flow / Net Income
NASDAQ-MNKD	$3.97	12.1% Upside	Fair	$7.97	125.1% Upside	Bargain	Good	0.0%	November 10, 2026	2.9x	1.141 B	1.471 B	27.4%	92.5%	-10.6	41.6%